Literature DB >> 18977818

Voxel-based analysis of cerebral glucose metabolism in mono- and dizygotic twins discordant for Alzheimer disease.

J J Virta1, S Aalto, T Järvenpää, M Karrasch, J Kaprio, M Koskenvuo, I Räihä, T Viljanen, J O Rinne.   

Abstract

BACKGROUND: Sporadic Alzheimer disease (AD) is a multifactorial disease to which both genetic and environmental factors contribute. Therefore, twin pairs are useful in studying its pathogenesis and aetiology. Cerebral glucose metabolism has been found to be reduced in AD patients.
METHODS: Cerebral glucose metabolism was studied in seven monozygotic (MZ) and nine same-sexed dizygotic (DZ) twin pairs discordant for AD using positron emission tomography. To obtain objective and explorative results concerning differences in glucose metabolism, the analysis was performed utilising modern voxel-based analysis methodology statistical parametric mapping and automated region-of-interest analysis.
RESULTS: In the demented MZ and DZ co-twins, cerebral glucose metabolism was extensively reduced compared with controls. The non-demented MZ co-twins showed reduced metabolism in inferior frontal, lateral temporal, parietal and medial temporal cortices as well as in the thalamus, putamen and right amygdala. In contrast, no reductions were found in the non-demented DZ co-twins. The reduction found in the non-demented MZ co-twins may be an indicator of genetic susceptibility to AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977818     DOI: 10.1136/jnnp.2008.145466

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  2 in total

Review 1.  The use of PET in Alzheimer disease.

Authors:  Agneta Nordberg; Juha O Rinne; Ahmadul Kadir; Bengt Långström
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

Review 2.  Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals.

Authors:  Maciej J Lazarczyk; Patrick R Hof; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  BMC Med       Date:  2012-10-25       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.